188
Results-
NewsPierre Fabre Laboratories Begins Next Chapter in Secaucus, NJCreated on : - Last modified on :SECAUCUS, NJ (June 18, 2025): Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world’s second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology.
-
Disclosure of Payments to Patient OrganisationsCreated on : - Last modified on :Disclosure of Payments to Patient Organisations Patient organizations provide a powerful voice for patients across Europe. They aim at improving the quality of life of people who suffer from diseases. They are an emotional support for patients, they help them and their carriers to better understand their illness and their care.
-
Home PageCreated on : - Last modified on :
-
Disclosure of Payments to Healthcare ProfessionalsCreated on : - Last modified on :Disclosure of Payments to Healthcare Professionals Our collaborations with healthcare professionals always aim to benefit patients, improve medical practices and patient care. Activities can range from clinical research to exchanges on how new medicines fit into patient pathway. We believe that a more open transparent relationship strengthens the basis for collaboration and is in the best interest of patients and all health stakeholders.
-
NewsPierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241Created on : - Last modified on :PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC")
-
NewsThe 2025 Annual Report, under the sign of a new energyCreated on : - Last modified on :Find the 2025 annual report (2024 figures) online.
-
Who We AreCreated on : - Last modified on :
-
NewsroomCreated on : - Last modified on :
-
Annual Report 2025 of Laboratories Pierre FabreCreated on : - Last modified on :
-
Press ReleaseLicense and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)Created on : - Last modified on :
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.